Eli Lilly And Co vs Quanta Services Inc — how do they compare? Eli Lilly And Co trades at $1,222.55 (market cap $1.08T), while Quanta Services Inc trades at $687.51 (market cap $100.82B). The key difference: Eli Lilly And Co is far larger — about 10.7× Quanta Services Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | PWR | |
|---|---|---|
Market Cap | $1.08T | $100.82B |
Sector | Health | Industrials |
52-Week High | $1.24K | $785.24 |
52-Week Low | $639.43 | $372.50 |
Enterprise Value | $1.13T | $106.91B |
Dividend Yield | 0.57% | 0.07% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
PWR trades at $680.97, up 3.04% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth, reaching $28.48B in 2025, and raised its 2026 outlook, supported by a record backlog and infrastructure demand. However, valuation ratios like a P/E of 76.73 and P/S of 3.1 are elevated, indicating high expectations.
The outlook is positive due to accelerating infrastructure investments and analyst consensus favoring buys, with a price target of $809.75. Risks include high valuation sensitivity, project execution challenges, and macroeconomic pressures on capital spending. Earnings growth remains the key catalyst for further upside, but investors should weigh premium pricing against execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →